Rheumnow Podcast

2026 EULAR Preview
Beyond BMI: Altered Body Composition in Rheumatoid Arthritis
CAR-T For Rheumatoid Arthritis
This Is a Woman’s World: Women's Health in Rheumatic Disease
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Doctor's Orders or Patient's Choice: BACH study findings
Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs
Digital Patient Education in RA
Making Methotrexate More Effective
Are we failing in the treatment of RA-ILD?
Using AI to Predict Progression to RA
Treat to Target Works in Elderly Onset RA
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Improving Referrals for Inflammatory Arthritis
Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

2026 EULAR Preview
Imaging in Subclinical Psoriatic Arthritis
Dietary Interventions in PsA
This Is a Woman’s World: Women's Health in Rheumatic Disease
Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA
Can We Stop PsA Before it Starts?
BE BOLD: Going Where No PsA Trial Has Gone Before
BMI Outranks Treatment in PsA Outcomes?
Debate: Combination Therapies for Inflammatory Arthritis?
Combination Biologics in PsA: MRI Findings from AFFINITY
Combination Therapy in SpA
The Case for Dual Pathway Blockade in Refractory PsA
The AFFINITY Study: Combination Treatment in PsA
PsA Potpourri: Probiotics & Head-to-Head Data
Transition from Psoriasis to Psoriatic Arthritis
MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA
Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial

 

2026 EULAR Preview
CAR-T For Rheumatoid Arthritis
What Happens when CAR-T Fails Managing Disease Recurrence
Management of Relapses After CAR-T Therapy in SLE, SSc and IIM
How Many CAR-Ts Do We Need to Test Drive?

Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Improving Referrals for Inflammatory Arthritis"
Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

Are we failing in the treatment of RA-ILD?
Using AI to Predict Progression to RA
Treat to Target Works in Elderly Onset RA

MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA
How Many CAR-Ts Do We Need to Test Drive?
Making Methotrexate More Effective

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Day 4 of the EULAR 2026 Congress. Abstracts discussed included:

LB001
LB002
LB003
LB005
LB007
LB009
RA Plenary
POS1350

Debate: Combination Therapies for Inflammatory Arthritis?
Combination Biologics in PsA: MRI Findings from AFFINITY
Combination Therapy in SpA
Digital Patient Education in RA
The Case for Dual Pathway Blockade in Refractory PsA
The AFFINITY Study: Combination Treatment in PsA
PsA Potpourri: Probiotics & Head-to-Head Data
Transition from Psoriasis to Psoriatic Arthritis

 

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 3 of the EULAR 2026 Congress. Abstracts discussed included:
OP0348 
POS0290 
OP0342 
POS1068 
POS0201 
POS0288

BE BOLD: Going Where No PsA Trial Has Gone Before
BMI Outranks Treatment in PsA Outcomes?
What Happens when CAR-T Fails Managing Disease Recurrence
Management of Relapses After CAR-T Therapy in SLE, SSc and IIM
Doctor's Orders or Patient's Choice: BACH study findings
Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs